Advertisement

Citrus aurantium

  • Anders Westanmo
Part of the Forensic Science and Medicine book series (FSM)

Abstract

Citrus aurantium has enjoyed a rich history of uses in food, cosmetics, and medicine Recent misuse of this product for weight loss, however, is threatening to tarnish the holistic reputation of this fruit Manufacturers are isolating and concentrating the synephnne content from the 0 33 mg/g contained in the pulp of whole fruit to 20 mg/g in some dietary supplements, and over 100-fold increase to 35 mg/g in extracts With the known cardiovascular effects of synephrine, this may be creating a potentially dangerous or abuseable supplement out of what people once safely enjoyed The use of C aurantium for weight loss has little support in the literature, but this has not stopped producers from marketing the drug for this purpose since the void left after the ban of ephedra The increased frequency in which case reports of toxicity have emerged since this product has started being used for weight loss should serve as a cautionary note for more vigilant monitoring of safety.

Key Words

Citrus aurantium bitter orange synephrine ephedra substitute weight loss adrenergic amines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Webber HJ. History and development of the citrus industry. In: Reuther W, Webber HJ, Batchelor LD, eds., The Citrus Industry, vol. 1. Berkeley University of California Press, 1967, pp. 1–39.Google Scholar
  2. 2.
    Webber HJ. Cultivated varieties of the citrus. In: Webber HJ, Batchelor DL, eds., The Citrus Industry, vol. 1. Berkeley: University of California Press, 1943, pp. 475–668.Google Scholar
  3. 3.
    Facciola S, Cornucopia II, eds. A Source Book of Edible Plants. Vista Kampong Publications, 1998.Google Scholar
  4. 4.
    Hosseinimehr SJ, Tavakoli H, Pourheirdari G, Sobhani A, Shafiee A. Radioprotective effects of citrus extract agains gamma-irradiation in mouse bone marrow cells. J Radiat Res 2003;44:237–241.PubMedCrossRefGoogle Scholar
  5. 5.
    Kiple KF, Ornelas KC, eds. The Cambridge World History of Food. Cambridge Cambridge University Press, Vol. 2, 2000, pp. 1822–1826.Google Scholar
  6. 6.
    Ramadan W, Mourad B, Ibrahim S, Sonbol F. Oil of bitter orange: new topical antifungal agent. Int J Dermatol 1996;35:448–449.PubMedCrossRefGoogle Scholar
  7. 7.
    Natural Medicines Comprehensive Database online, http://www.naturaldatabase.com. Date accessed: June 15, 2006.
  8. 8.
    FDA Drug Information, http://www.fda.gov/cder/drug/infopage/ppa/. Date accessed June 15 2006.
  9. 9.
    Department of Health and Human Services, Food and Drug Administration 2004; 1–363. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. www.fda.gov/OHRMS/ DOCKETS/98fr/1995n-0304-nfr0001.pdf. Date accessed: June 15, 2006.Google Scholar
  10. 10.
    Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003;289:1537–1545.PubMedCrossRefGoogle Scholar
  11. 11.
    Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833–1838.PubMedCrossRefGoogle Scholar
  12. 12.
    Bent S, Tiedt TN, Odden MC, Shlipak MG. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003;138:468–471.PubMedGoogle Scholar
  13. 13.
    Marcus DM, Grollman AP. Ephedra-free is not danger free. Science 2003;301:1667–1671.CrossRefGoogle Scholar
  14. 14.
    Preuss HG, DiFerdinando D, Bagchi M, Bagchi D. Citrus aurantium as a thermogenic, weight-reduction replacement for ephedra: an overview. J Med 2002; 33(1–4):247–264.PubMedGoogle Scholar
  15. 15.
    Fugh-Berman A, Myers A. Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. Exp Biol Med 2004;229:698–704.Google Scholar
  16. 16.
    Bent S, Padula A, Neuhaus J. S afety and efficacy of Citrus aurantium for weight loss. Am J Cardiol 2004;94:1359–1361.PubMedCrossRefGoogle Scholar
  17. 17.
    United States Patent and Trademark Office, http://www.uspto.gov/patft. Search terms: citrus and aurantium. Date accessed: June 15, 2006.
  18. 18.
    Pellati F, Benvenuti S, Melegari M, Firenzuoli F. Determination of adrenergic agonists from extracts and herbal products of Citrus aurantium L. var by LC. J Pharm Biomed Anal 2002;29:1113–1119.PubMedCrossRefGoogle Scholar
  19. 19.
    Pellati F, Benvenuti S, Melegari M. High-performance liquid chromatography methods for the analysis of adrenergic amines and flavanones in Citrus aurantium L. var. amara. Phytochem Anal 2004; 15:220–225.PubMedCrossRefGoogle Scholar
  20. 20.
    Andrea GD, Terrazzino S, Fortin D, Farruggio A, Rinaldi L, Leon A. HPLC electrochemical detection of trace amines in human plasma and platelets and expression of mRNA transcripts of trace amine receptors in circulating leukocytes. Neurosci Lett 2003;346:89–92.PubMedCrossRefGoogle Scholar
  21. 21.
    Boulton AA. Trace amines: comparative and clinical neurobiology. In: Juorio AV, Downer RGH, eds. Experimental and Clinical Neuroscience. Totowa, NJ Humana, 1988.Google Scholar
  22. 22.
    Pellati F, Benvenuti S, Melegari M. Enantioselective LC analysis of synephrine in natural products on a protein-based chiral stationary phase. J Pharm Biomed Anal 2005;37(5):839–849.PubMedCrossRefGoogle Scholar
  23. 23.
    Hoffman BB. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, eds., Goodman and Gilman’s the Pharmacologic Basis for Therapeutics, 10th edition. New York McGraw Hill: 2001, pp. 215–268.Google Scholar
  24. 24.
    Williams CM, Couch MW, Thonoor CM, Midgley JM. Isomeric octopamines: their occurrence and functions. J Pharm Pharmacol 1987;39:153–157.PubMedGoogle Scholar
  25. 25.
    Hwa J, Perez DM. The unique nature of the serine interactions for al-adrenergic receptor agonist binding and activation. J Biol Chem 1996;271(ll):6322–6327.PubMedGoogle Scholar
  26. 26.
    Brown CM, McGrath JC, Midgley JM, et al. Activities of octopamine and synephrine stereoisomers on alpha-adrenoceptors. Br J Pharmacol 1988;93:417–429.PubMedGoogle Scholar
  27. 27.
    Airriess CN, Rudling JE, Midgley JM, Evans PD. Selective inhibition of adenylyl cyclase by octopamine via ahuman cloned alpha 2A-adrenoreceptor. Br J Pharmacol 1997;12(2):191–198.CrossRefGoogle Scholar
  28. 28.
    Jordan R, Midgley JM, Thonoor CM, Williams CM. Beta-adrenergic activities of octopamine and synephrine stereoisomers on guinea-pig atria and trachea. J Pharm Pharmacol 1987;39(9):752–754.PubMedGoogle Scholar
  29. 29.
    Liapakis G, Baiesteros JA, Papachristou S, Chan WC, Chen X, Javitch JA. The forgotten serine: a critical role for Ser-203 in ligand binding to and activation of the β2-adrenergic receptor. J Biol Chem 2000;275(48):37, 779–837,788.CrossRefGoogle Scholar
  30. 30.
    Carpene C, Galitzky J, Fontana E, Atgie C, Lafontan MB. Selective activation of β3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Arch Pharmacol 1999;359(4):310–321.CrossRefGoogle Scholar
  31. 31.
    Huang YT, Wang GF, Chen CF, Chen CC, Hong CY, Yang MCM. Fructus aurantii reduced portal pressure in portal hypertensive rats. Life Sci 1995;57:2011–2020.PubMedCrossRefGoogle Scholar
  32. 32.
    Calapai G, Firenzuoli F, Saitta A, et al. Antiobesity and cardiovascular effects of Citrus aurantium extraces in the rat: a preliminary report. Fitoterapia 1999;70:586–592.CrossRefGoogle Scholar
  33. 33.
    Huang YT, Lin HC, Chang YY, Yang YY, Lee SD, Hong CY. Hemodynamic effects of synephrine treatment in portal hypertensive rats. Jpn J Pharmacol 2001;85:183–188.PubMedCrossRefGoogle Scholar
  34. 34.
    HofstetterR, Kreuder J, von Bernuth G. The effect of oxedrine on the left ventricle and peripheral vascular resistance. Arzneimittelforschung 1985; 12:1844–1846.Google Scholar
  35. 35.
    Penzak SR, Jann MW, Cold A, Hon YY, Desai HD, Gurley BJ. Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults. J Clin Pharmacol 2001;41:1059–1063.PubMedCrossRefGoogle Scholar
  36. 36.
    Colker CM, Kaiman DS, Torina GC, Perlis T, Street C. Effects of Citrus aurantium extract, caffeine, and St. John’s wort on body fat loss, lipid levels, and mood states in overweight healthy adults. Curr Ther Res 1999;60:145–153.CrossRefGoogle Scholar
  37. 37.
    Kaddu S, Kerl H, Wolf P. Accidental bullous phototoxic reactions to bergamot aromatherapy oil. J Am Acad Dermatol 2001;45(3):458–461.PubMedCrossRefGoogle Scholar
  38. 38.
    Zaynoun ST, Aftimos BA, Tenekjian KK, Kurban AK. Berloque dermatitis — a continuing cosmetic problem. Contact Dermatitis 1981;7(2): 111–116.PubMedCrossRefGoogle Scholar
  39. 39.
    Chew A, Maibach H. Berloque Dermatitison. eMedicine 2001. http://www.emedicine.com/derm/topic52.htm. Date accessed: June 15, 2006.
  40. 40.
    Makki S, Treffel P, Humbert P, Agache P. High-performance liquid Chromatographic determination of citropten and bergapten in suction blister fluid after solar product application in humans. J Chromatogr 1991;563:407–413.PubMedCrossRefGoogle Scholar
  41. 41.
    Clark SM, Wilkinson SM. Phototoxic contact dermatitis from 5-methoxypsoralen in aromatherapy oil. Contact Dermatitis 1998;38:289–290.PubMedCrossRefGoogle Scholar
  42. 42.
    Levine N, Don S, Owens C, Rogers DT, Kligman AM, Forlot P. The effects of bergapten and sunlight on cutaneous pigmentation. Arch Dermatol 1989;125:1225–1230.PubMedCrossRefGoogle Scholar
  43. 43.
    Ashwood-Smith MJ, Poulton GA, Barker M, Mildenberger M. 5-Methoxypsoralen, an ingredient in several suntan preparations, has lethal mutagenic and clastogenic properties. Nature 1980;285:407–409.PubMedCrossRefGoogle Scholar
  44. 44.
    Nykamp DL, Fackih MN, Compton AL. Possible association of acute lateral-wall myocardial infarction and bitter orange supplement. Ann Pharmacother 2004;38:812–816.PubMedCrossRefGoogle Scholar
  45. 45.
    Firenzuoli F, Gori L, Galapai C. Adverse reaction to an adrenergic herbal extract (Citrus aurantium). Phytomedicine 2005;12(3):247–248.PubMedCrossRefGoogle Scholar
  46. 46.
    Jordan S, Murty M, Pilon K. Products containing bitter orange or synephrine: suspected cardiovascular adverse reactions. Can Adverse React Newsl 2004; 14(4):3–4.Google Scholar
  47. 47.
    Health Canada warns Canadians not to use “Thermonex.” Ottawa: Health Canada, 2004. http://www.hc-sc.gc.ca/english/protection/warnings/2004/2004_30.htm. Date accessed: November 28, 2004.
  48. 48.
    Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001;69:14–23.PubMedCrossRefGoogle Scholar
  49. 49.
    Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP. The effect of grapefruit juice and Seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A4 and p-glycoprotein. Life Sci 2002;71:l 149–1160.Google Scholar
  50. 50.
    Malhotra S, Fitzsimmons ME, Bailey DG, Watkins PB. Use of Seville orange juice to “knock out” intestinal CYP3A4. Paper presented at the annual meeting of the American Association of Pharmaceutical Scientists (abstract 2091), New Orleans, LA, November 1999.Google Scholar
  51. 51.
    Hou YC, Hsiu SL, Tsao CW, Wang YH, Chao PD. Acute intoxication of cyclosporine caused by coadministration of decoctions of the fruits of Citrus aurantium and the Pericaps of Citrus grandis. Planta Med 2000;66(7):653–655.PubMedCrossRefGoogle Scholar
  52. 52.
    Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6’7’-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 1999;65:237–244.PubMedCrossRefGoogle Scholar
  53. 53.
    Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004;76(5):428–440.PubMedCrossRefGoogle Scholar
  54. 54.
    Keogh AM, Baron DW. Sympathomimetic abuse and coronary artery spasm. Br Med J 1985;291:940.CrossRefGoogle Scholar
  55. 55.
    Suzuki O, Matsumoto T, Oya M, Katsumata Y. Oxidation of synephrine by type A and type B monoamine oxidase. Experientia 1979;35:1283–1284.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Anders Westanmo

There are no affiliations available

Personalised recommendations